## Pieter Wesseling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/216845/publications.pdf

Version: 2024-02-01

325 papers 39,925 citations

80 h-index 187 g-index

336 all docs

336 docs citations

336 times ranked 37940 citing authors

#	Article	IF	CITATIONS
1	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	10.7	6,451
2	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	1.2	4,534
3	Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. Brain Pathology, 2009, 19, 674-693.	4.1	2,884
4	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
5	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 397-405.	7.7	914
6	Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates, 2015, 19, 1-12.	14.4	706
7	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
8	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell, 2015, 28, 666-676.	16.8	700
9	The immunosuppressive tumour network: myeloidâ€derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 2013, 138, 105-115.	4.4	643
10	<scp>WHO</scp> 2016 Classification of gliomas. Neuropathology and Applied Neurobiology, 2018, 44, 139-150.	3.2	612
11	Diffuse glioma growth: a guerilla war. Acta Neuropathologica, 2007, 114, 443-458.	7.7	513
12	<scp>I</scp> nternational <scp>S</scp> ociety of <scp>N</scp> europathologyâ€ <scp>H</scp> aarlem <scp>C</scp> onsensus <scp>G</scp> uidelines for <scp>N</scp> ervous <scp>S</scp> ystem <scp>T</scp> umor <scp>C</scp> lassification and <scp>G</scp> rading. Brain Pathology, 2014, 24, 429-435.	4.1	499
13	<i>IDH1</i> and <i>IDH2</i> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 2010, 16, 1597-1604.	7.0	364
14	clMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the clMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
15	DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Research, 2014, 24, 2022-2032.	<b>5.</b> 5	362
16	Germline Mutation of INI1/SMARCB1 in Familial Schwannomatosis. American Journal of Human Genetics, 2007, 80, 805-810.	6.2	360
17	EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Annals of Oncology, 2017, 28, iv84-iv99.	1,2	331
18	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320

#	Article	IF	CITATIONS
19	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for $1p/19q$ non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
20	Clinical and pathologic abnormalities in a family with parkinsonism and <i>parkin</i> gene mutations. Neurology, 2001, 56, 555-557.	1.1	288
21	clMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	7.7	281
22	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	7.7	272
23	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathologica, 2015, 129, 585-596.	7.7	272
24	Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica, 2010, 120, 567-584.	7.7	243
25	In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma. Cancer Cell, 2010, 18, 244-257.	16.8	238
26	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
27	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell, 2017, 32, 238-252.e9.	16.8	235
28	Development and developmental disorders of the human cerebellum. Journal of Neurology, 2003, 250, 1025-1036.	3.6	223
29	Glioma: experimental models and reality. Acta Neuropathologica, 2017, 133, 263-282.	7.7	223
30	Development of a decision support system for diagnosis and grading of brain tumours usingin vivo magnetic resonance single voxel spectra. NMR in Biomedicine, 2006, 19, 411-434.	2.8	216
31	Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option. Clinical Cancer Research, 2004, 10, 6222-6230.	<b>7.</b> O	213
32	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology, 2009, $11$ , $394-402$ .	1.2	203
33	Angiogenesis in brain tumors; pathobiological and clinical aspects. Journal of Neuro-Oncology, 1997, 32, 253-265.	2.9	202
34	CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responsesin vivo. International Journal of Cancer, 2007, 121, 95-105.	5.1	199
35	Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathology and Applied Neurobiology, 2006, 32, 119-130.	3.2	197
36	Heparan sulphate proteoglycans in Alzheimer's disease and amyloidâ€related disorders. Lancet Neurology, The, 2003, 2, 482-492.	10.2	192

3

#	Article	IF	CITATIONS
37	Histologic classification of gliomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 71-95.	1.8	190
38	Receptor conversion in distant breast cancer metastases. Breast Cancer Research, 2010, 12, R75.	5.0	189
39	Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring. Cancer Research, 2018, 78, 3407-3412.	0.9	188
40	Prognostic significance and mechanism of Treg infiltration in human brain tumors. Journal of Neuroimmunology, 2010, 225, 195-199.	2.3	180
41	Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 809-827.	7.7	162
42	MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Laboratory Investigation, 2007, 87, 1055-1065.	3.7	161
43	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncology, 2014, 16, 1263-1273.	1.2	159
44	Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. American Journal of Pathology, 1994, 144, 372-82.	3.8	155
45	Cerebrotendinous Xanthomatosis: The Spectrum of Imaging Findings and the Correlation with Neuropathologic Findings. Radiology, 2000, 217, 869-876.	7.3	147
46	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	7.7	145
47	Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathologica, 2015, 129, 597-607.	7.7	143
48	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	1.2	143
49	Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme. Journal of Neuropathology and Experimental Neurology, 1995, 54, 304-310.	1.7	132
50	Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell, 2004, 5, 151-162.	16.8	132
51	Adjuvant and concurrent temozolomide for $1p/19q$ non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 Oncology, The, 2021, 22, 813-823.	1 0.78431 10.7	14 rgBT /0\ 132
52	Molecular pathology of tumors of the central nervous system. Annals of Oncology, 2019, 30, 1265-1278.	1.2	129
53	Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathologica, 2010, 119, 317-323.	7.7	128
54	Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Research, 2002, 62, 341-5.	0.9	128

#	Article	IF	CITATIONS
55	Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. Journal of Neurosurgery, 2006, 105, 6-14.	1.6	126
56	Agrin Is a Major Heparan Sulfate Proteoglycan Accumulating in Alzheimer's Disease Brain. American Journal of Pathology, 1999, 155, 2115-2125.	3.8	123
57	Announcing clMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
58	Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express \$100A8/9 and arginase and suppress T cell function. Neuro-Oncology, 2016, 18, 1253-1264.	1.2	119
59	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	1.2	119
60	Development and malformations of the human pyramidal tract. Journal of Neurology, 2004, 251, 1429-1442.	3.6	117
61	In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma. PLoS ONE, 2013, 8, e61512.	2.5	108
62	Collision sellar lesions: experience with eight cases and review of the literature. Pituitary, 2010, 13, 8-17.	2.9	107
63	A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. Clinical Cancer Research, 2011, 17, 7148-7155.	7.0	107
64	<i>MGMT</i> -STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. Clinical Cancer Research, 2013, 19, 5513-5522.	7.0	106
65	Multiplex Ligation-Dependent Probe Amplification. Journal of Molecular Diagnostics, 2006, 8, 433-443.	2.8	105
66	RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathologica, 2007, 114, 121-133.	7.7	105
67	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of Oncology, 2015, 26, 1994-1999.	1.2	105
68	Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Journal of Neurosurgery, 1994, 81, 902-909.	1.6	101
69	Significance of complete $1p/19q$ co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Modern Pathology, 2013, 26, 922-929.	5.5	100
70	Molecular pathogenesis of oligodendroglial tumors. Journal of Neuro-Oncology, 2004, 70, 161-181.	2.9	99
71	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. Journal of Clinical Oncology, 2013, 31, 328-336.	1.6	99
72	Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Molecular Cancer Therapeutics, 2008, 7, 71-78.	4.1	98

#	Article	IF	CITATIONS
73	Mycâ€associated zinc finger protein (MAZ) is regulated by miRâ€125b and mediates VEGFâ€induced angiogenesis in glioblastoma. FASEB Journal, 2012, 26, 2639-2647.	0.5	98
74	Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue. Journal of Neuropathology and Experimental Neurology, 2015, 74, 390-400.	1.7	98
75	Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Human Pathology, 1998, 29, 352-358.	2.0	95
76	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
77	Heparan sulfate proteoglycan expression in cerebrovascular amyloid $\hat{l}^2$ deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathologica, 2001, 102, 604-614.	7.7	93
78	Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects. Brain Pathology, 2015, 25, 209-226.	4.1	88
79	Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathologica, 2005, 109, 321-328.	7.7	87
80	Identification of Subgroups of High-grade Oligodendroglial Tumors by Comparative Genomic Hybridization. Journal of Neuropathology and Experimental Neurology, 1999, 58, 606-612.	1.7	83
81	Prognostic value of estrogen receptor $\hat{l}_{\pm}$ and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	4.1	81
82	Liquid biopsies in patients with diffuse glioma. Acta Neuropathologica, 2015, 129, 849-865.	7.7	81
83	Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. American Journal of Pathology, 2017, 187, 940-953.	3.8	80
84	Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3. Brain, 2004, 127, 2551-2557.	7.6	79
85	p120-catenin-dependent collective brain infiltration by glioma cell networks. Nature Cell Biology, 2020, 22, 97-107.	10.3	79
86	Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain, 1999, 122, 1589-1595.	7.6	77
87	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 2012, 123, 841-852.	7.7	77
88	AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS. Journal of Pathology, 1996, 179, 436-442.	4.5	75
89	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . Neuro-Oncology, 2021, 23, 34-43.	1.2	75
90	Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 2014, 128, 605-607.	7.7	74

#	Article	IF	Citations
91	Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. American Journal of Pathology, 1994, 144, 104-16.	3.8	74
92	Successful Treatment of Fusarium Keratitis with Cornea Transplantation and Topical and Systemic Voriconazole. Clinical Infectious Diseases, 2005, 40, e110-e112.	5.8	73
93	Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Research, 2003, 63, 5408-13.	0.9	72
94	Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. British Journal of Cancer, 2008, 98, 474-479.	6.4	71
95	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology, 2009, 11, 737-746.	1.2	71
96	Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment. Angiogenesis, 2017, 20, 533-546.	7.2	71
97	Accurate classification of childhood brain tumours by in vivo 1H MRS – A multi-centre study. European Journal of Cancer, 2013, 49, 658-667.	2.8	70
98	Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2. PLoS ONE, 2013, 8, e58262.	2.5	70
99	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discovery, 2022, 12, 331-355.	9.4	70
100	Collagen XVIII: a Novel Heparan Sulfate Proteoglycan Associated with Vascular Amyloid Depositions and Senile Plaques in Alzheimer's Disease Brains. Brain Pathology, 2002, 12, 456-462.	4.1	69
101	Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics. Brain Pathology, 2009, 19, 661-671.	4.1	69
102	Keratitis Caused by Scedosporium apiospermum Successfully Treated with a Cornea Transplant and Voriconazole. Journal of Clinical Microbiology, 2003, 41, 2261-2264.	3.9	68
103	Phenotypic and Genotypic Characterization of Orthotopic Human Glioma Models and Its Relevance for the Study of Antiâ€glioma Therapy. Brain Pathology, 2008, 18, 423-433.	4.1	67
104	Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. Journal of Pathology, 2002, 197, 238-244.	4.5	66
105	Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiology of Aging, 2002, 23, 537-545.	3.1	64
106	Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. Journal of Extracellular Vesicles, 2018, 7, 1446660.	12.2	64
107	Human pontine glioma cells can induce murine tumors. Acta Neuropathologica, 2014, 127, 897-909.	7.7	63
108	Third harmonic generation imaging for fast, label-free pathology of human brain tumors. Biomedical Optics Express, 2016, 7, 1889.	2.9	63

7

#	Article	IF	Citations
109	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784 27, 851-852.	1314 rgBT 4.1	/Overlock 10 63
110	Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI International Journal of Cancer, 2003, 105, 437-443.	5.1	62
111	Histological effects of fibrin glue on nervous tissue. World Neurosurgery, 2002, 57, 415-422.	1.3	61
112	Protein tyrosine phosphatases in glioma biology. Acta Neuropathologica, 2010, 119, 157-175.	7.7	61
113	Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic <i>NRAS</i> in Melanocytes. Cancer Discovery, 2013, 3, 458-469.	9.4	61
114	Reconstructing the molecular life history of gliomas. Acta Neuropathologica, 2018, 135, 649-670.	7.7	61
115	Counting mitoses: SI(ze) matters!. Modern Pathology, 2021, 34, 1651-1657.	5.5	61
116	Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathologica, 2010, 120, 755-764.	7.7	60
117	Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro-Oncology, 2020, 22, 412-422.	1.2	59
118	Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy, 2021, 17, 2604-2612.	9.1	59
119	Brain tumour diagnostics using a DNA methylationâ€based classifier as a diagnostic support tool. Neuropathology and Applied Neurobiology, 2020, 46, 478-492.	3.2	59
120	Glioblastomas exploit truncated O <i>-</i> linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3693-3703.	7.1	57
121	Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. British Journal of Cancer, 1997, 76, 561-570.	6.4	56
122	Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. British Journal of Cancer, 2008, 98, 1784-1789.	6.4	56
123	The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. Diagnostic Histopathology, 2011, 17, 486-494.	0.4	56
124	Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. Journal of Pathology, 2001, 194, 81-87.	4.5	55
125	MAPK pathway activation through <i>BRAF</i> gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. Journal of Pathology, 2010, 222, 324-328.	4.5	54
126	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and $\hat{l}_{\pm}$ -KG. Acta Neuropathologica Communications, 2013, 1, 18.	5.2	54

#	Article	IF	CITATIONS
127	Monitoring of Tumor Growth and Postâ€Irradiation Recurrence in a Diffuse Intrinsic Pontine Glioma Mouse Model. Brain Pathology, 2011, 21, 441-451.	4.1	53
128	Giant cavernous hemangiomas: report of three cases. Neurosurgical Review, 2007, 30, 83-92.	2.4	52
129	Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Reports Medicine, 2020, 1, 100101.	6.5	52
130	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	7.7	52
131	Magnetic resonance imagingâ€based detection of glial brain tumors in mice after antiangiogenic treatment. International Journal of Cancer, 2008, 122, 1981-1986.	5.1	51
132	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2166-2174.	4.1	51
133	Diffuse glioneuronal tumour with oligodendrogliomaâ€like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathology and Applied Neurobiology, 2020, 46, 422-430.	3.2	51
134	Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma. Cancer Immunology, Immunotherapy, 2019, 68, 937-949.	4.2	49
135	Hypokinesia and presenile dementia in a Dutch family with a novel insertion in the prion protein gene. Brain, 1995, 118, 1565-1571.	7.6	47
136	Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. Journal of Neurosurgery, 2002, 96, 559-564.	1.6	47
137	Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene, 2007, 26, 5808-5815.	5.9	47
138	Discordance in $\mathrm{ER}\hat{1}_{\pm}$ , PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Annals of Oncology, 2013, 24, 3017-3023.	1.2	47
139	Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathologica Communications, 2014, 2, 41.	<b>5.</b> 2	47
140	Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. Journal of Comparative Neurology, 2005, 486, 243-253.	1.6	46
141	Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget, 2018, 9, 20134-20155.	1.8	46
142	Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. Acta Neuropathologica, 1993, 85, 508-14.	7.7	44
143	Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiotherapy and Oncology, 1995, 35, 118-122.	0.6	44
144	Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology, 2011, 59, 1-7.	2.9	44

#	Article	IF	CITATIONS
145	3′-Deoxy-3′- <sup>18</sup> F-Fluorothymidine PET–Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients. Journal of Nuclear Medicine, 2012, 53, 1904-1910.	5.0	44
146	Amyloid-beta-induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype. Annals of the New York Academy of Sciences, 2000, 903, 187-199.	3.8	43
147	Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathologica, 2015, 130, 131-144.	7.7	43
148	Progression of a Nelson's adenoma to pituitary carcinoma; a case report and review of the literature. Journal of Endocrinological Investigation, 1999, 22, 70-75.	3.3	42
149	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. American Journal of Neuroradiology, 2017, 38, 1884-1891.	2.4	42
150	The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neuro-Oncology Practice, 2021, 8, 4-10.	1.6	42
151	EFEMP1 induces î <sup>3</sup> -secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget, 2014, 5, 363-374.	1.8	41
152	Hypoxia in a human intracerebral glioma model. Journal of Neurosurgery, 2000, 93, 449-454.	1.6	40
153	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
154	Choroid Plexus Carcinoma: A Report of Two Cases and Review of the Literature. Neuropediatrics, 1996, 27, 143-148.	0.6	39
155	Overexpression of the natural antisense hypoxia-inducible factor- $1\hat{A}$ transcript is associated with malignant pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2011, 18, 323-331.	3.1	39
156	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 66-74.	7.4	39
157	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathology, 2016, 26, 199-205.	4.1	39
158	Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro-Oncology, 2018, 20, 642-654.	1.2	39
159	Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the <scp>M</scp> arseille <scp>G</scp> rading <scp>S</scp> ystem in a cohort of 132 patients. Brain Pathology, 2019, 29, 18-27.	4.1	39
160	Retroclival Extradural Hematoma Is a Magnetic Resonance Imaging Diagnosis. Journal of Neurotrauma, 2001, 18, 1289-1293.	3.4	38
161	A novel seven-octapeptide repeat insertion in the prion protein gene (PRNP) in a Dutch pedigree with Gerstmannâ $\in$ "Str $\tilde{A}$ ussler $\tilde{a}\in$ "Scheinker disease phenotype: comparison with similar cases from the literature. Acta Neuropathologica, 2011, 121, 59-68.	7.7	38
162	Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion Journal of Clinical Oncology, 2019, 37, 2000-2000.	1.6	38

#	Article	IF	CITATIONS
163	Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours. Neuropathology and Applied Neurobiology, 2015, 41, 743-755.	3.2	37
164	Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A'-containing lesions in brains of patients with dementia of the Alzheimer type. Acta Neuropathologica, 1996, 91, 608-615.	7.7	36
165	The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin ?v?3 expression. International Journal of Cancer, 2001, 92, 176-180.	5.1	36
166	Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 560-575.	7.4	36
167	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	7.7	36
168	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	1.5	35
169	Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. Scientific Reports, 2014, 4, 5260.	3.3	35
170	SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. Acta Neuropathologica Communications, 2016, 4, 5.	5.2	35
171	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Letters, 2014, 344, 138-146.	7.2	34
172	Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms. Pathology and Oncology Research, 2015, 21, 439-447.	1.9	34
173	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34
174	Three-dimensional reconstruction of tumor microvasculature: Simultaneous visualization of multiple components in paraffin-embedded tissue. Angiogenesis, 2006, 8, 297-305.	7.2	33
175	Pituitary apoplexy after mild head injury misinterpreted as bacterial meningitis. European Journal of Neurology, 2007, 14, e7-e8.	3.3	33
176	A pilot study on slit lamp-adapted optical coherence tomography imaging of trabeculectomy filtering blebs. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 877-882.	1.9	33
177	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	1.2	33
178	Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. Journal of Neuro-Oncology, 1999, 44, 129-136.	2.9	32
179	Neuromyelitis optica with clinical and histopathological involvement of the brain. Multiple Sclerosis Journal, 2007, 13, 679-682.	3.0	32
180	Alphaâ€internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer, 2011, 117, 3014-3026.	4.1	32

#	Article	IF	CITATIONS
181	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer, 2014, 14, 864.	2.6	32
182	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
183	Mitochondrial cytopathy presenting as hereditary sensory neuropathy with progressive external ophthalmoplegia, ataxia and fatal myoclonic epileptic status. Brain, 1996, 119, 997-1010.	7.6	31
184	Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma. Journal of Neuro-Oncology, 2018, 140, 403-412.	2.9	31
185	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	7.7	31
186	A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques. Acta Neuropathologica, 1995, 90, 493-503.	7.7	30
187	Transalar Sphenoidal Encephalocele and Respiratory Distress in a Neonate: A Case Report. Pediatrics, 1999, 103, e12-e12.	2.1	30
188	Comparative Genomic Hybridization: Practical Guidelines. Diagnostic Molecular Pathology, 2002, 11, 193-203.	2.1	30
189	Meningioma of the Pituitary Stalk without Dural Attachment: Case Report and Review of the Literature. Neurosurgery, 1999, 45, 1474-1477.	1.1	29
190	Quantitative short echo time <sup>1</sup> H MRSI of the peripheral edematous region of human brain tumors in the differentiation between glioblastoma, metastasis, and meningioma. Journal of Magnetic Resonance Imaging, 2012, 36, 1072-1082.	3.4	29
191	Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biology, 2014, 15, 471.	8.8	29
192	Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. Journal of Neuro-Oncology, 2001, 52, 241-247.	2.9	28
193	Analysis of von Hippelâ€"Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. Journal of Neurosurgery, 2002, 97, 977-982.	1.6	28
194	Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility. Oncotarget, 2014, 5, 8690-8702.	1.8	28
195	Multivoxel 1H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Neuro-Oncology, 2013, 15, 1615-1624.	1.2	27
196	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
197	Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis. Journal of Neurosurgery, 2005, 103, 702-706.	1.6	26
198	Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. Journal of Pathology, 2011, 223, 626-634.	4.5	26

#	Article	IF	CITATIONS
199	Primary intracranial germ-cell tumors in adults: a practical review. Journal of Neuro-Oncology, 2013, 113, 175-183.	2.9	26
200	SMARCB1 Involvement in the Development of Leiomyoma in a Patient With Schwannomatosis. American Journal of Surgical Pathology, 2014, 38, 421-425.	3.7	25
201	<i>In vivo</i> MR guided boiling histotripsy in a mouse tumor model evaluated by MRI and histopathology. NMR in Biomedicine, 2016, 29, 721-731.	2.8	25
202	Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. International Journal of Cancer, 2006, 119, 2054-2062.	5.1	24
203	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	2.9	24
204	Implementation of a multiâ€institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture. Neuropathology and Applied Neurobiology, 2013, 39, 426-436.	3.2	24
205	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2018, 59, 612-615.	5.0	24
206	Quantitative Third Harmonic Generation Microscopy for Assessment of Glioma in Human Brain Tissue. Advanced Science, 2019, 6, 1900163.	11.2	24
207	Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization. Journal of Neurosurgery, 2000, 92, 652-658.	1.6	23
208	Premature termination of SMARCB1 translation may be followed by reinitiation in schwannomatosis-associated schwannomas, but results in absence of SMARCB1 expression in rhabdoid tumors. Acta Neuropathologica, 2014, 128, 439-448.	7.7	23
209	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Journal of Neurosurgery: Pediatrics, 2017, 19, 518-530.	1.3	23
210	Optical genome mapping identifies a germline retrotransposon insertion in <scp><i>SMARCB1</i></scp> in two siblings with atypical teratoid rhabdoid tumors. Journal of Pathology, 2021, 255, 202-211.	4.5	23
211	Postmortem Findings in the Nijmegen Breakage Syndrome. Pediatric Pathology, 1994, 14, 787-796.	0.5	22
212	Inverse Correlation between Genetic Aberrations and Malignancy Grade in Ependymal Tumors: A Paradox?. Journal of Neuro-Oncology, 2004, 66, 111-116.	2.9	22
213	Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma. Acta Neuropathologica Communications, 2016, 4, 96.	5.2	22
214	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
215	Distinct Differences in Binding Capacity to Saccharide Epitopes in Supratentorial Pilocytic Astrocytomas, Astrocytomas, Anaplastic Astrocytomas, and Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2001, 60, 75-84.	1.7	21
216	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. Archives of Pathology and Laboratory Medicine, 2020, 144, 196-206.	2.5	21

#	Article	IF	CITATIONS
217	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without $1p/19q$ co-deletion: An Intergroup trial Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	1.6	20
218	Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Oncotarget, 2017, 8, 60447-60452.	1.8	20
219	Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastoma., 2012, 3, 158.		20
220	Neuropathological diagnostic accuracy. British Journal of Neurosurgery, 2002, 16, 461-464.	0.8	19
221	Intestinal mucosa on top of a rudimentary occipital meningocele in amniotic rupture sequence: disorganization-like syndrome, homeotic transformation, abnormal surface encounter or endoectodermal adhesion?. Clinical Dysmorphology, 2002, 11, 9-13.	0.3	19
222	Molecular Diagnostics as a Tool to Personalize Treatment in Adult Glioma Patients. Technology in Cancer Research and Treatment, 2006, 5, 215-229.	1.9	19
223	The Nature and Timing of Specific Copy Number Changes in the Course of Molecular Progression in Diffuse Gliomas: Further Elucidation of Their Genetic "Life Story― Brain Pathology, 2011, 21, 308-320.	4.1	19
224	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study). Neurosurgery, 2016, 79, 535-540.	1.1	19
225	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. Cell Reports, 2018, 22, 3206-3216.	6.4	19
226	Prognostic significance of NAB2–STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear. Acta Neuropathologica, 2019, 137, 679-682.	7.7	19
227	Spatial concordance of DNA methylation classification in diffuse glioma. Neuro-Oncology, 2021, 23, 2054-2065.	1.2	19
228	The Aicardi-Goutières syndrome: Variable clinical expression in two siblings. Pediatric Neurology, 1997, 16, 323-325.	2.1	18
229	lleus in mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. Netherlands Journal of Medicine, 1998, 53, 27-31.	0.5	18
230	Compatibility between 3TÂ1H SV-MRS data and automatic brain tumour diagnosis support systems based on databases of 1.5T 1H SV-MRS spectra. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 35-42.	2.0	18
231	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	7.7	18
232	CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 481-491.	6.4	17
233	Intramedullary enterogenous cyst presenting with spastic paraparesis during two consecutive pregnancies: a case report. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 528-530.	1.9	16
234	White Matter Lesions Are Not Related to $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Amyloid Deposition in an Autopsy-Based Study. Current Gerontology and Geriatrics Research, 2011, 2011, 1-5.	1.6	15

#	Article	IF	Citations
235	Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas. Melanoma Research, 2015, 25, 200-209.	1.2	15
236	Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. Experimental and Molecular Pathology, 2017, 102, 25-31.	2.1	15
237	A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule. Journal of Endocrinological Investigation, 2006, 29, 934-939.	3.3	14
238	Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. Acta Oncol $\tilde{A}^3$ gica, 2011, 50, 462-465.	1.8	14
239	Incremental Gaussian Discriminant Analysis based on Graybill and Deal weighted combination of estimators for brain tumour diagnosis. Journal of Biomedical Informatics, 2011, 44, 677-687.	4.3	14
240	Technical feasibility of integrating 7ÂT anatomical MRI in image-guided radiotherapy of glioblastoma: a preparatory study. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 591-603.	2.0	14
241	Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Research, 2018, 8, 72.	2.5	14
242	Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis, 2006, 9, 201-208.	7.2	13
243	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. Neuro-Oncology, 2014, 16, 400-408.	1.2	13
244	Embryonal tumor with multilayered rosettes (ETMR): signed, sealed, delivered …. Acta Neuropathologica, 2014, 128, 305-308.	7.7	13
245	Cyclin D1 Genotype and Expression in Sporadic Hemangioblastomas. Journal of Neuro-Oncology, 2005, 74, 261-266.	2.9	12
246	Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation. Child's Nervous System, 2008, 24, 855-857.	1.1	12
247	Can Excision of Meningiomas Be Limited to Resection of Tumor and Radiologically Abnormal Dura Mater? Neuronavigation-Guided Biopsies of Dural Tail and Seemingly Normal Dura Mater, with a Review of the Literature. World Neurosurgery, 2014, 82, e832-e836.	1.3	12
248	Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity. Molecular Cancer Research, 2017, 15, 1587-1597.	3.4	12
249	Radiotherapy for partially resected spinal ependymomas: A retrospective study of 60 cases. Oncology Reports, 2003, 10, 2079-82.	2.6	12
250	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers, 2022, 14, 126.	3.7	12
251	Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Scientific Reports, 2016, 6, 30486.	3.3	11
252	Severe, non X-linked congenital microcephaly with absence of the pyramidal tracts in two siblings. Acta Neuropathologica, 1999, 98, 203-211.	7.7	10

#	Article	IF	Citations
253	Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. Journal of Alzheimer's Disease, 2004, 6, 469-474.	2.6	10
254	Fast intraoperative histology-based diagnosis of gliomas with third harmonic generation microscopy and deep learning. Scientific Reports, 2022, 12, .	3.3	10
255	Differential patterns of insulin-like growth factor-I and -II mRNA expression in medulloblastoma. Neuropathology and Applied Neurobiology, 2004, 30, 503-512.	3.2	9
256	Development and Developmental Disorders of the Human Cerebellum. , 2014, , 371-420.		9
257	Impact of MR-guided boiling histotripsy in distinct murine tumor models. Ultrasonics Sonochemistry, 2017, 38, 1-8.	8.2	9
258	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurologic Clinics, 2018, 36, 421-437.	1.8	9
259	A case of Joubert's syndrome with extensive cerebral malformations., 2000, 19, 85-93.		9
260	Type 1 papillary renal cell carcinoma in a patient with schwannomatosis: Mosaic versus loss of <scp>SMARCB</scp> 1 expression in respectively schwannoma and renal tumor cells. Genes Chromosomes and Cancer, 2016, 55, 350-354.	2.8	8
261	Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. EJNMMI Research, 2019, 9, 57.	2.5	8
262	Molecular tools for the pathologic diagnosis of central nervous system tumors. Neuro-Oncology Practice, 2019, 6, 4-16.	1.6	8
263	Quantitative parametric maps of O-(2-[ <sup>18</sup> F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 895-903.	4.3	8
264	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without $1p/19q$ co-deletion: An Intergroup trial Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	1.6	8
265	The relationship between genetic aberrations as detected by comparative genomic hybridization and vascularization in glioblastoma xenografts. Journal of Neuro-Oncology, 2001, 51, 121-127.	2.9	7
266	Cerebral Amyloid Angiopathy with Severe Secondary Vascular Pathology: A Histopathological Study. Dementia and Geriatric Cognitive Disorders, 2005, 20, 321-330.	1.5	7
267	Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 331-336.	2.8	7
268	Genetics and pharmacogenomics of diffuse gliomas. , 2013, 137, 78-88.		7
269	A clinicopathologic study of 11 rosette-forming meningiomas: a rare and potentially confusing pattern. Acta Neuropathologica, 2015, 130, 311-313.	7.7	7
270	Demyelination and axonal dystrophy in alpha A-crystallin transgenic mice. International Journal of Experimental Pathology, 2001, 81, 271-282.	1.3	6

#	Article	IF	CITATIONS
271	A spinal intradural enterogenous cyst with well-differentiated muscularis propria. Acta Neuropathologica, 2002, 104, 538-542.	7.7	6
272	Molecular Analysis as a Tool in the Differential Diagnosis of VHL Disease-Related Tumors. Diagnostic Molecular Pathology, 2005, 14, 115-120.	2.1	6
273	Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions. European Journal of Surgical Oncology, 2010, 36, 957-962.	1.0	6
274	Towards an integrated morphological and molecular WHO diagnosis of central nervous system tumors. Current Opinion in Neurology, 2015, 28, 628-632.	3.6	6
275	Unique Presentation of Corneal Opacity in Peters Plus Syndrome. Cornea, 2016, 35, 277-280.	1.7	6
276	A Uniform Histological Cluster Scheme for ICD-O-Coded Primary Central Nervous System Tumors. Neuroepidemiology, 1998, 17, 233-246.	2.3	5
277	Virilization due to ovarian androgen hypersecretion in a patient with ectopic adrenocorticotrophic hormone secretion caused by a carcinoid tumour: Case Report. Human Reproduction, 2006, 21, 2601-2605.	0.9	5
278	Computer-assisted analysis of the microvasculature in untreated glioblastomas. Journal of Neuro-Oncology, 1995, 24, 83-85.	2.9	4
279	Scheie Syndrome Presenting as Myopathy. Neuropediatrics, 2001, 32, 93-96.	0.6	4
280	Development and Developmental Disorders of the Human Cerebellum. , 2006, , 309-344.		4
281	Molecular diagnostics of brain tumors. Acta Neuropathologica, 2010, 120, 549-551.	7.7	4
282	Re: a Word of Caution on New and Revolutionary Diagnostic Tests. Cancer Cell, 2016, 29, 143-144.	16.8	4
283	Taxonomy of <scp>CNS</scp> tumours; a series of three short reviews on the <scp>WHO</scp> 2016 classification and beyond. Neuropathology and Applied Neurobiology, 2018, 44, 137-138.	3.2	4
284	A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques. Acta Neuropathologica, 1995, 90, 493-503.	7.7	4
285	QUANTITATIVE ANALYSIS OF MICROVASCULAR CHANGES DURING MALIGNANT PROGRESSION IN ASTROCYTIC NEOPLASMS. Journal of Neuropathology and Experimental Neurology, 1996, 55, 607.	1.7	4
286	Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1489-1491.	1.9	3
287	RE: MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION FOR THE DETECTION OF 1P AND 19Q LOSS IN OLIGODENDROGLIAL TUMORS. Brain Pathology, 2005, 15, 364-364.	4.1	3
288	Fatal consequences of an ear infection. Lancet, The, 2009, 373, 1658.	13.7	3

#	Article	IF	Citations
289	Contribution of CSF cytology in the diagnostic work-up of breast cancer patients with neurological symptoms: a retrospective analysis over two decades. Journal of Neuro-Oncology, 2012, 107, 581-589.	2.9	3
290	Copy number variations as potential diagnostic and prognostic markers for CNS melanocytic neoplasms in neurocutaneous melanosis. Acta Neuropathologica, 2017, 133, 333-335.	7.7	3
291	An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid. Human Genetics and Genomics Advances, 2020, 1, 100006.	1.7	3
292	Paraneoplastic non-caseating granulomatous inflammation of the eyelid. British Journal of Ophthalmology, 1995, 79, 617-617.	3.9	2
293	The cochlear nuclei in two patients with Usher syndrome type I. International Journal of Pediatric Otorhinolaryngology, 1999, 50, 185-195.	1.0	2
294	PROGNOSTIC VALUE OF MICROVASCULAR PARAMETERS IN DIFFUSE ASTROCYTIC NEOPLASMS. Journal of Neuropathology and Experimental Neurology, 1999, 58, 535.	1.7	2
295	Immunotherapy of Diffuse Gliomas: Helping the Brain Fight Back!. Brain Pathology, 2009, 19, 672-673.	4.1	2
296	Classification of Gliomas. , 2013, , 3-20.		2
297	Ranking of Brain Tumour Classifiers Using a Bayesian Approach. Lecture Notes in Computer Science, 2009, , 1005-1012.	1.3	2
298	A new technique for the assessment of the draining area of a cerebral vein. World Neurosurgery, 1999, 52, 78-80.	1.3	1
299	Successful third-line chemotherapy for an adult with recurrent medulloblastoma. International Cancer Conference Journal, 2014, 3, 32-37.	0.5	1
300	The ABCs of molecular diagnostic testing of CNS tumors: acceptance, benefits, costs. Neuro-Oncology, 2019, 21, 559-561.	1.2	1
301	Abstract 3426: A novel approach to copy number assessment by whole genome sequencing reveals extensive spatial heterogeneity in diffuse low-grade glioma. , 2014, , .		1
302	The Cerebellum. , 2020, , 539-589.		1
303	MICROVASCULAR CELL-SUBSTRATUM INTEGRINS AND EXTRACELLULAR MATRIX PROTEINS IN HUMAN GLIOBLASTOMA MULTIFORME. Journal of Neuropathology and Experimental Neurology, 1995, 54, 439.	1.7	0
304	Infantile motor neuron disease with autonomic dysfunction and bunina bodies. Acta Neuropathologica, 1998, 95, 104-106.	7.7	0
305	PERICYTES IN GLIOBLASTOMAS CONTRIBUTE TO ENZYMATIC DEGRADATION OF ANGIOTENSIN II. Journal of Neuropathology and Experimental Neurology, 1998, 57, 504.	1.7	0
306	P3-167 Specific association of small heat shock proteins with the pathological features of Alzheimer's and Parkinson's disease brains. Neurobiology of Aging, 2004, 25, S403.	3.1	0

#	Article	IF	CITATIONS
307	The Biology of Brain Tumors. Neuroradiology Journal, 2008, 21, 7-9.	1.2	0
308	The Cerebellum., 2011,, 449-493.		0
309	GE-08 * TARGETED NEXT GENERATION SEQUENCING OF ARCHIVAL FFPE SAMPLES FROM EORTC STUDY 26951 SHOWS STRONG PROGNOSTIC VALUE OF A MOLECULAR CLASSIFICATION IN LOCALLY DIAGNOSED GRADE III OLIGODENDROGLIOMA. Neuro-Oncology, 2014, 16, v97-v97.	1.2	0
310	Glioblastoma: Pathology and Genetics. , 2018, , .		0
311	SURG-13. THIRD HARMONIC GENERATION (THG) IMAGING: A NOVEL TOOL FOR INTRA-OPERATIVE HISTOLOGIC ANALYSIS OF FRESH HUMAN GLIOMA TISSUE. Neuro-Oncology, 2018, 20, vi253-vi253.	1.2	0
312	MBRS-36. IDENTIFICATION OF TWO PROTEIN-SIGNALING STATES DELINEATING TRANSCRIPTIONALLY HETEROGENEOUS HUMAN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i136-i136.	1.2	0
313	Pathology and Classification of Tumors of theÂCentral Nervous System. , 2019, , 3-89.		0
314	Is Overexpression of the Hypoxia-Inducible Factor-1alpha Natural Antisense Transcript a Marker of the Malignant Potential of Phaeochromocytoma?, 2010,, P3-619-P3-619.		0
315	Glial Brain Tumors: Antiangiogenic Therapy. , 2011, , 109-119.		0
316	Tumoren van het zenuwstelsel. , 2011, , 501-512.		0
317	Abstract 3775: Identification of PHF6 as a temozolomide resistance factor in glioblastoma using mirConnX., 2014,,.		0
318	Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer Journal of Clinical Oncology, 2015, 33, 11058-11058.	1.6	0
319	Tumoren van het zenuwstelsel. , 2017, , 499-512.		0
320	Liquid Biopsy Diagnosis of CNS Metastases. , 2020, , 73-86.		0
321	PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE. Neuro-Oncology, 2021, 23, vi119-vi120.	1.2	O
322	EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT. Neuro-Oncology, 2021, 23, vi3-vi3.	1.2	0
323	EPCO-17. METHYLATION ANALYSIS OF MATCHED PRIMARY AND RECURRENT IDHmt ASTROCYTOMA; AN UPDATE FROM THE GLIOMA LONGITUDINAL ANALYSIS NL (GLASS-NL) CONSORTIUM. Neuro-Oncology, 2021, 23, vi5-vi5.	1.2	0
324	QOLP-05. HEALTH-RELATED QUALITY OF LIFE IN LOW-GRADE GLIOMA SURVIVORS 26 YEARS AFTER DIAGNOSIS. Neuro-Oncology, 2021, 23, vi183-vi183.	1.2	0

#	Article	IF	CITATIONS
325	Rare CNS tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas and intracranial germ cell tumors. Neuro-Oncology Advances, 0, , .	0.7	0